- Home
- MUFG vs SNY Comparison
MUFG vs SNY Comparison
Compare MUFG & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MUFG
- SNY
- Stock Information
- Founded
- MUFG 1880
- SNY 1994
- Country
- MUFG Japan
- SNY France
- Employees
- MUFG N/A
- SNY N/A
- Industry
- MUFG Commercial Banks
- SNY Biotechnology: Pharmaceutical Preparations
- Sector
- MUFG Finance
- SNY Health Care
- Exchange
- MUFG Nasdaq
- SNY Nasdaq
- Market Cap
- MUFG 143.3B
- SNY 134.4B
- IPO Year
- MUFG 2001
- SNY N/A
- Fundamental
- Price
- MUFG $12.66
- SNY $54.46
- Analyst Decision
- MUFG
- SNY Strong Buy
- Analyst Count
- MUFG 0
- SNY 1
- Target Price
- MUFG N/A
- SNY $60.00
- AVG Volume (30 Days)
- MUFG 2.9M
- SNY 2.4M
- Earning Date
- MUFG 02-04-2025
- SNY 01-30-2025
- Dividend Yield
- MUFG 2.09%
- SNY 4.04%
- EPS Growth
- MUFG 37.26
- SNY 2.94
- EPS
- MUFG 0.96
- SNY 4.60
- Revenue
- MUFG $39,430,543,625.00
- SNY $45,849,466,833.00
- Revenue This Year
- MUFG N/A
- SNY $9.02
- Revenue Next Year
- MUFG $6.20
- SNY $6.31
- P/E Ratio
- MUFG $13.32
- SNY $23.70
- Revenue Growth
- MUFG 69.42
- SNY 7.73
- 52 Week Low
- MUFG $8.75
- SNY $45.22
- 52 Week High
- MUFG $13.34
- SNY $58.97
- Technical
- Relative Strength Index (RSI)
- MUFG 52.58
- SNY 62.24
- Support Level
- MUFG $12.31
- SNY $53.46
- Resistance Level
- MUFG $13.34
- SNY $55.04
- Average True Range (ATR)
- MUFG 0.17
- SNY 0.70
- MACD
- MUFG 0.01
- SNY -0.09
- Stochastic Oscillator
- MUFG 33.50
- SNY 75.32
About MUFG Mitsubishi UFJ Financial Group Inc.
Mitsubishi UFJ Financial Group is the largest bank in Japan in terms of market capitalization and assets, with an 8.0% share of all domestic loans as of March 2024. It is the largest non-Chinese bank group globally and has a balance sheet slightly larger than those of JPMorgan Chase and HSBC Holdings. MUFG's operations in Japan account for around half of profit, banking in Thailand and Indonesia for around 15%, and equity-method earnings from Morgan Stanley most of the rest.
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, over-the-counter treatments and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 20% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.